LA, S., J, F., P, I. V., SJ, L., H, W., E, N., . . . ES, A. (2021). Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. The oncologist, 26(2), e270. https://doi.org/10.1002/onco.13601
Chicago Style (17th ed.) CitationLA, Sena, et al. "Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer." The Oncologist 26, no. 2 (2021): e270. https://doi.org/10.1002/onco.13601.
MLA (9th ed.) CitationLA, Sena, et al. "Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer." The Oncologist, vol. 26, no. 2, 2021, p. e270, https://doi.org/10.1002/onco.13601.
Warning: These citations may not always be 100% accurate.
